Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 9/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 6/20 | 1.00 |
| ▸ | KDR | P35968 | 6/20 | 1.00 |
| ▸ | MAP3K11 | Q16584 | 6/20 | 1.00 |
| ▸ | MAP3K9 | P80192 | 5/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 4/20 | 1.00 |
| ▸ | PRKCG | P05129 | 4/20 | 1.00 |
| ▸ | PRKCB | P05771 | 4/20 | 1.00 |
| ▸ | PRKCA | P17252 | 4/20 | 1.00 |
| ▸ | PRKCH | P24723 | 4/20 | 1.00 |
| ▸ | PRKCI | P41743 | 4/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 4/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 4/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 4/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 4/20 | 1.00 |
| ▸ | MAP3K10 | Q02779 | 4/20 | 1.00 |
| ▸ | MYLK | Q15746 | 3/20 | 1.00 |
| ▸ | CDK4 | P11802 | 2/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| K-252A SCHEMBL29434956 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL13993461 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL31181849 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL29355962 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL13485248 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL15575821 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL24112155 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL13787898 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL32665760 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL29660621 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372338-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | FOUNDATION MEDICINE, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-11771698-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-07-13 | — | — | US | disclosed |
| US-11578372-B2 | NTRK1 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-11230589-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210283134-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | FOUNDATION MEDICINE, INC. (US) | 2021-09-16 | — | — | US | disclosed |
| WO-2021076993-A1 | COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOTIC CELLS | ORCHARD THERAPEUTICS (EUROPE) LIMITED (GB) | 2021-04-22 | — | — | WO | disclosed |
| US-10980804-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200299775-A1 | NOVEL NTRK1 FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2020-09-24 | — | — | US | disclosed |
| US-20140135377-A1 | COMBINATION THERAPY | TURUN YLIOPISTO (FI) | 2014-05-15 | — | — | US | disclosed |
| WO-2014071358-A2 | NOVEL NTRK1 FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-8440443-B1 | MEK1 polypeptides | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110020326-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-01-27 | — | — | US | disclosed |
| US-20100179318-A1 | PROCESS TO MAKE LESTAURTINIB | ABBOTT LABORATORIES (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179318-A1 | PROCESS TO MAKE LESTAURTINIB | ABBOTT LABORATORIES (US) | 2010-07-15 | — | — | US | disclosed |
| US-20090239271-A1 | FERMENTATION BROTH EXTRACTION OF K-252A | ABBOTT LABORATORIES (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239271-A1 | FERMENTATION BROTH EXTRACTION OF K-252A | ABBOTT LABORATORIES (US) | 2009-09-24 | — | — | US | disclosed |
| US-20080299215-A1 | DEUTERIUM-ENRICHED LESTAURTINIB | PROTIA, LLC (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080081078-A1 | Prevention of Cell Proliferation by Inhibiting Myosin Light Chain Kinase | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578372-B2 | NTRK1 fusion molecules and uses thereof | NTRK1, NTRK3, NTRK2 | NTRK1 1/4885PRKCQ 1306/4885KDR 227/4885 |
| US-20080299215-A1 | DEUTERIUM-ENRICHED LESTAURTINIB | DLST, ABL1, THPO | NTRK1 3211/4885PRKCQ 3156/4885KDR 4028/4885 |
| US-11230589-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | NTRK1 1138/4885PRKCQ 3164/4885KDR 1552/4885 |
| US-20230372338-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | HCCS, PNLIP, LIPA | NTRK1 2894/4885PRKCQ 117/4885KDR 2368/4885 |
| US-10980804-B2 | Methods of treating cholangiocarcinoma | HCCS, PNLIP, LIPA | NTRK1 2894/4885PRKCQ 117/4885KDR 2368/4885 |
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | HSP90AB1, HSP90AA1, HSF1 | NTRK1 2265/4885PRKCQ 1402/4885KDR 4524/4885 |
| US-20080081078-A1 | Prevention of Cell Proliferation by Inhibiting Myosin Light Chain Kinase | MYLK3, MYLK, MYLK4 | NTRK1 3593/4885PRKCQ 379/4885KDR 2749/4885 |
| US-20200299775-A1 | NOVEL NTRK1 FUSION MOLECULES AND USES THEREOF | NTRK1, NTRK3, NTRK2 | NTRK1 1/4885PRKCQ 1265/4885KDR 337/4885 |
| US-20140135377-A1 | COMBINATION THERAPY | MCL1, PTPMT1, MTMR1 | NTRK1 3772/4885PRKCQ 1486/4885KDR 2155/4885 |
| US-20210283134-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | HCCS, PNLIP, LIPA | NTRK1 2894/4885PRKCQ 117/4885KDR 2368/4885 |
| US-20100179318-A1 | PROCESS TO MAKE LESTAURTINIB | FIP1L1, CYP1B1, FER | NTRK1 3191/4885PRKCQ 507/4885KDR 1003/4885 |
| US-11771698-B2 | Methods of treating cholangiocarcinoma | HCCS, PNLIP, LIPA | NTRK1 2894/4885PRKCQ 117/4885KDR 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.